CONTEXT: Publication of abstracts through ASCO on patient derived RWE on two very interesting areas of oncology. The first abstract looks at the reasons behind the low levels of trial Continue Reading
CONTEXT: Commercial announcement of a RWE tie-up between C-Path Institute and Tufts. IMPACT: Low READ TIME: 1 min Quality Level Mean [1 – 10]: 5 1. “”This will significantly add Continue Reading
CONTEXT: Despite the headline news that RWE shows no real improvement for mesothelioma patients, if you get down to the end of the article, there is promising news with the Continue Reading
CONTEXT: “Ground-breaking” can be an overused word, like “Leading company” or “Bitcoin”, but this research gets close to being worthy of the title. This author may be a little too Continue Reading
CONTEXT: Commercial announcement of a tie up between TriNetX and Takeda to develop the latter’s use of RWD in their overall trail design strategy. IMPACT: Low READ TIME: 1 min Continue Reading
CONTEXT: Novrtis going old school with the announcement of a global Phase 3b study in children with spinal muscular atrophy (SMA). Respect to Novartis for making the announcement and calling Continue Reading
CONTEXT: Commercial announcement of an RWE report updated for 2020 to 2030 claiming to cover a wide range of information about providers of RWE services and future trends in RWE. Continue Reading
CONTEXT: It’s awards season and as we wait to see who will be glammed up from the waist up at the Oscars, another RWE report is issued with even bigger Continue Reading
CONTEXT: Commercial merger announcement. Advise caution with regards to applicability in RWR as the technology platform is heavily clinical research focused. IMPACT: Low READ TIME: 1 min *1. “MUNICH–(BUSINESS WIRE)–XClinical, Continue Reading
CONTEXT: BMJ article describing a framework for RWE study design toencourage reproducibility. The framework is intended for use in studieslooking at effectiveness and safety of medical products and claims to Continue Reading
